Table 5.
Reference | Year | Treatment regimen | Median survival (mo) | p | HR | 95% CI |
Louvet | 2005 | Gemcitabine | 7.1 | 0.13 | 0.82 | 0.64 – 1.05 |
Gemcitabine (FDR) + Oxaliplatin | 9.0 | |||||
Poplin | 2006 | Gemcitabine (standard) | 4.9 | -- | 0.83* | 0.69 – 1.00 |
Gemcitabine (FDR) | 6.0 | -- | 0.88** | 0.73 – 1.05 | ||
Gemcitabine (FDR) + Oxaliplatin | 5.9 | |||||
Heinemann | 2006 | Gemcitabine | 6.0 | 0.15 | 0.80 | 0.59 – 1.08 |
Gemcitabine + Cisplatin | 7.5 | |||||
Colucci | 2002 | Gemcitabine | 5.0 | 0.48 | 0.87 | 0.58 – 1.29 |
Gemcitabine + Cisplatin | 7.5 | |||||
Viret | 2004 | Gemcitabine | 6.7 | 0.73 | 0.92 | 0.59 – 1.45 |
Gemcitabine + Cisplatin | 8.0 |
FDR = fixed dose rate;
* FDR Gemcitabine versus Gemcitabine
** GEMOX versus Gemcitabine